FULL-YEAR 2018 SALES WORLDWIDE 30.6 +7...*Organic sales growth excludes prior year results for the...
1
FULL-YEAR 2018 FINANCIAL RESULTS FULL-YEAR 2018 SALES WORLDWIDE +7.3 % 1 on organic basis * STRONG PERFORMANCE IN CORE BUSINESS SEGMENTS 2 sales on organic basis* DIAGNOSTICS NUTRITION ESTABLISHED PHARMACEUTICALS MEDICAL DEVICES +6.7 % +5.2 % +7.0 % FULL-YEAR 2019 GUIDANCE 3 $ 3.15 to $ 3.25 ADJUSTED EPS 30+ KEY PRODUCT ADVANCEMENTS IN 2018 +9.1 % $ 30.6 billion Shaping the future of healthcare WITH A ROBUST PRODUCT PIPELINE DELIVERING IMPRESSIVE GROWTH THROUGH A STRONG PRODUCT PIPELINE FreeStyle Libre® system: Our revolutionary sensor-based continuous glucose monitoring system is one of the world’s fastest-growing medical devices – with more than 1 million users. Alinity™: Our new suite of diagnostic systems offers leapfrog-level innovation to provide ease of use, greater flexibility and a smaller laboratory footprint. Structural Heart portfolio: Our minimally invasive solutions span the spectrum of heart valve disease and congenital heart defects. CREATING SHAREHOLDER VALUE 14.3 % dividend increase for 2019 payouts returned to shareholders in the form of dividends in 2018 $ 2B REPAID MORE THAN of debt, enhancing our strategic flexibility $ 8B INCLUDING: Amplatzer Piccolo™ Occluder, U.S. Pedialyte® Sparkling Rush™, U.S. HeartMate 3™, Long- Term Indication, U.S. DRG Invisible Trial System, U.S. FreeStyle Libre® 2, Europe FreeStyle Libre® 14 Day, U.S. High Sensitive Troponin-I, Expanded Indication, Europe MitraClip®, COAPT Trial, U.S. MitraClip®, U.S. and Japan Ensure® Max Protein, U.S. Advisor™ HD, U.S. Xience Sierra®, U.S. and Japan Masters HP™, U.S. MIDPOINT REFLECTS DOUBLE-DIGIT GROWTH *Organic sales growth excludes prior year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter of 2017; excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on October 3, 2017; excludes the prior year fourth-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 23, 2019. 1 On a GAAP basis, Abbott sales increased 11.6%. 2 On a GAAP basis, Diagnostics sales increased 33.5%; Medical Devices sales increased 10.1%; Nutrition sales increased 4.4%; and Established Pharmaceuticals sales increased 3.2%. 3 Adjusted EPS excludes specified items. Full-year 2019 GAAP guidance of $1.80 to $1.90. FORWARD-LOOKING STATEMENTS Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,’’ to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Transcript of FULL-YEAR 2018 SALES WORLDWIDE 30.6 +7...*Organic sales growth excludes prior year results for the...
FULL-YEAR 2018FINANCIAL RESULTS
FULL-YEAR 2018 SALES WORLDWIDE
+7.3%1
on organic basis*
STRONG PERFORMANCE IN CORE BUSINESS SEGMENTS2
sales on organic basis*
DIAGNOSTICS
NUTRITION ESTABLISHED PHARMACEUTICALS
MEDICAL DEVICES
+6.7%
+5.2% +7.0%
FULL-YEAR 2019 GUIDANCE3
$3.15 to $3.25A DJ U S T E D E P S
30+ K E Y P R O D U C T A D VA N C E M E N T S I N 2018
+9.1%
$30.6billion
Shaping the future of healthcareWITH A ROBUST
PRODUCT PIPELINE
D E L I V E R I N G I M P R E S S I V E G R O W T H T H R O U G H A S T R O N G P R O D U C T P I P E L I N EFreeStyle Libre® system: Our revolutionary sensor-based continuous glucose monitoring system is one of the world’s fastest-growing medical devices – with more than 1 million users.
Alinity™: Our new suite of diagnostic systems offers leapfrog-level innovation to provide ease of use, greater flexibility and a smaller laboratory footprint.
Structural Heart portfolio: Our minimally invasive solutions span the spectrum of heart valve disease and congenital heart defects.
C R E AT I N G S H A R E H O L D E R VA L U E
14.3%dividend increase for 2019 payouts
returned to shareholders in the form of dividends in 2018
$2BREPAID MORE THAN
of debt, enhancing our strategic flexibility
$8B
INCLUDING:
Amplatzer Piccolo™ Occluder, U.S.
Pedialyte® Sparkling Rush™, U.S.
HeartMate 3™, Long-Term Indication, U.S.
DRG Invisible Trial System, U.S.
FreeStyle Libre® 2, Europe
FreeStyle Libre® 14 Day, U.S.
High Sensitive Troponin-I, Expanded Indication, Europe
MitraClip®, COAPT Trial, U.S.
MitraClip®, U.S. and Japan
Ensure® Max Protein, U.S.
Advisor™ HD, U.S.
Xience Sierra®, U.S. and Japan
Masters HP™, U.S.
MIDPOINT REFLECTS DOUBLE-DIGIT GROWTH
*Organic sales growth excludes prior year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter of 2017; excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on October 3, 2017; excludes the prior year fourth-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 23, 2019.1On a GAAP basis, Abbott sales increased 11.6%.2On a GAAP basis, Diagnostics sales increased 33.5%; Medical Devices sales increased 10.1%; Nutrition sales increased 4.4%; and Established Pharmaceuticals sales increased 3.2%.3Adjusted EPS excludes specified items. Full-year 2019 GAAP guidance of $1.80 to $1.90.
FORWARD-LOOKING STATEMENTS Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,’’ to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
